Recruiting
Acute lymphocytic leukaemia+1
RecruitingStudy of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma
InvestigationalNo placebo
Study of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma
InvestigationalNo placebo
- Disease:Acute lymphocytic leukaemiaNon-Hodgkin's lymphoma
- Substances:TDT-3
Countries:
Norway
Norway- Participants:0–17 years · 18–64 years · 65+ years
- Substances:TDT-3
